Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, before market open, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.3 per share.
Looking ahead, the full year loss are expected at $ 1.17 per share.
Stock Performance
Shares of Galmed Pharmaceuticals Ltd. traded up $ 0.23 or 7.35 percent on Wednesday, reaching $ 3.36 with volume of 81.00 thousand shares. Galmed Pharmaceuticals Ltd. has traded high as $ 3.38 and has cracked $ 3.17 on the downward trend
The closing price of $ 3.36, representing a 5.74 % increase from the 52 week low of $ 2.96 and a 57.59 % decrease over the 52 week high of $ 7.38.
The company has a market capital of $ 70.94 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Galmed Pharmaceuticals Ltd. will be hosting a conference call at 8:30 AM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 1-877-425-9470 Toll Free, (United States) or 1-201-389-0878 (International), with passcode : 13711943 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.galmedpharma.com
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
